175 related articles for article (PubMed ID: 36877344)
21. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
[TBL] [Abstract][Full Text] [Related]
22. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
Mi L; Liu J; Zhang Y; Su A; Tang M; Xing Z; He T; Wei T; Li Z; Wu W
Phytomedicine; 2024 Jul; 129():155670. PubMed ID: 38704915
[TBL] [Abstract][Full Text] [Related]
23. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
Lee HJ; Lee WK; Kang CW; Ku CR; Cho YH; Lee EJ
Cancer Lett; 2018 Mar; 417():131-140. PubMed ID: 29306020
[TBL] [Abstract][Full Text] [Related]
24. Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways.
Li L; Wang X; Sharvan R; Gao J; Qu S
Biomed Pharmacother; 2017 Nov; 95():1225-1231. PubMed ID: 28931215
[TBL] [Abstract][Full Text] [Related]
25. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
[TBL] [Abstract][Full Text] [Related]
26. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
De Martino D; Yilmaz E; Orlacchio A; Ranieri M; Zhao K; Di Cristofano A
Cancer Lett; 2018 Dec; 439():56-65. PubMed ID: 30243708
[TBL] [Abstract][Full Text] [Related]
27. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Cancer Stem-Like Phenotype by Curcumin and Deguelin in CAL-62 Anaplastic Thyroid Cancer Cells.
Kocdor MA; Cengiz H; Ates H; Kocdor H
Anticancer Agents Med Chem; 2019; 19(15):1887-1898. PubMed ID: 31584382
[TBL] [Abstract][Full Text] [Related]
29. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.
Mehta A; Zhang L; Boufraqech M; Liu-Chittenden Y; Zhang Y; Patel D; Davis S; Rosenberg A; Ylaya K; Aufforth R; Li Z; Shen M; Kebebew E
Clin Cancer Res; 2015 Sep; 21(18):4123-32. PubMed ID: 25944801
[TBL] [Abstract][Full Text] [Related]
31. Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.
Xu Q; Mackay RP; Xiao AY; Copland JA; Weinberger PM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669447
[TBL] [Abstract][Full Text] [Related]
32. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.
Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP
J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549
[TBL] [Abstract][Full Text] [Related]
33. SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.
Wang P; Shang J; Zhao J; Wang K; Guo L; Gu J; Wang W
Mol Med Rep; 2020 Mar; 21(3):1201-1207. PubMed ID: 31922212
[TBL] [Abstract][Full Text] [Related]
34. Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
Zhang L; Boufraqech M; Lake R; Kebebew E
Oncotarget; 2016 Mar; 7(13):16517-28. PubMed ID: 26934320
[TBL] [Abstract][Full Text] [Related]
35. [Study on the Biological Function of Abemecilib in Inhibiting the Proliferation, Invasion and
Migration of Small Cell Lung Cancer with High c-Myc Expression].
Guo J; Mu D; Yu W; Sun L; Zhang J; Ren X; Han Y
Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):105-112. PubMed ID: 36872049
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
[TBL] [Abstract][Full Text] [Related]
37. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
Yan P; Su Z; Zhang Z; Gao T
Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
[TBL] [Abstract][Full Text] [Related]
38. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
[TBL] [Abstract][Full Text] [Related]
39. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.
Che HY; Guo HY; Si XW; You QY; Lou WY
Tumour Biol; 2014 Sep; 35(9):8659-64. PubMed ID: 24867098
[TBL] [Abstract][Full Text] [Related]
40. Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines.
Nozhat Z; Mohammadi-Yeganeh S; Azizi F; Zarkesh M; Hedayati M
Daru; 2018 Dec; 26(2):93-103. PubMed ID: 30242671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
